Answers are grounded in this paper and cite their sources.
Bispecific antibodies (BsAbs) have demonstrated efficacy in newly diagnosed and relapsed/refractory (R/R) lymphomas.BsAbs form immune synapses between effector cells (T cells) and target cell surface markers; typically, CD19 and CD20 in B-cell lymphomas.BsAb use in myeloma has raised concerns about increased infection risk 1 ; less is known about infection rates after BsAb treatment for lymphoma.Three CD20-directed BsAbs are now available for lymphoma as standard of care, and approvals across jurisdictions such as the United States, Canada, and Europe are evolving rapidly. 2 US Food and Drug Administration (FDA) approvals were largely based on small phase 1b/2 studies in heterogenous populations with different dosing schedules, treatment durations, and supportive care protocols.Despite regulatory approvals, there are no guidelines for anti-infective prophylaxis and an incomplete understanding of the rates, timing, and types of infections experienced.Therefore, a systematic review and meta-analysis were undertaken to better characterize infection risks associated with BsAb therapy.
No takes yet. Share an insight, caveat, or question.
Reynolds et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: